-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KEcZ0bWmJQtpEkuL9c7O5Hn6dy4vjYbGkqSOQioaNT2vt16lkWvrGhS6i4N8Ekc4 sgEztDwfh9dQ7hq9sutGSQ== 0000830736-08-000011.txt : 20080813 0000830736-08-000011.hdr.sgml : 20080813 20080812212125 ACCESSION NUMBER: 0000830736-08-000011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080812 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20080813 DATE AS OF CHANGE: 20080812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALPHA INNOTECH CORP CENTRAL INDEX KEY: 0000830736 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 581729436 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14257 FILM NUMBER: 081011323 BUSINESS ADDRESS: STREET 1: 2401 MERCED ST. CITY: SAN LEANDRO STATE: CA ZIP: 94577 BUSINESS PHONE: 5104839620 MAIL ADDRESS: STREET 1: 2401 MERCED ST. CITY: SAN LEANDRO STATE: CA ZIP: 94577 FORMER COMPANY: FORMER CONFORMED NAME: XTRANA INC DATE OF NAME CHANGE: 20010702 FORMER COMPANY: FORMER CONFORMED NAME: BIOPOOL INTERNATIONAL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: CYTRX BIOPOOL LTD DATE OF NAME CHANGE: 19890716 8-K 1 body8_kerq208.htm FORM 8-K EARNINGS RELEASE FOR Q2 2008 body8_kerq208.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 12, 2008
 
ALPHA INNOTECH CORP.
(Exact name of registrant as specified in its charter)
 
         
Delaware
 
1-14257
 
58-1729436
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
     
2401 Merced Street, San Leandro, California
 
94577
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (510) 483-9620
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(B))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4c))
 
 

 
 

 


Item 2.02.
Results of Operations and Financial Condition
 
On August 12, 2008, Alpha Innotech Corp. (the “Company”) issued a press release announcing its earnings for the fiscal quarter ended June 30, 2008, the text of which is attached hereto as Exhibit 99.1.
 
The information in this Item 2.02 of the Current Report on Form 8-K, including the exhibit, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in the Item 2.02 of the Current Report on Form 8-K, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.
 
Item 9.01.
Financial Statements and Exhibits
 
(d) Exhibits
 
     
99.1
  
Press Release dated August 12, 2008 announcing earnings for the fiscal quarter ended June 30, 2008
 
2

 
 

 


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
                 
           
ALPHA INNOTECH CORP.
       
Date: August 12, 2008
     
By:
 
/s/ Ron Bissinger
               
Ron Bissinger
Chief Executive Officer and Chief Financial Officer
 
3

 
 

 


EXHIBIT INDEX
 
     
99.1
  
Press Release dated August 12, 2008 announcing earnings for the fiscal quarter ended June 30, 2008
 
4


 
 

 

EX-99.1 2 ex99_1.htm EX 99.1 EARNINGS RELEASE FOR Q2 2008 ex99_1.htm
Exhibit 99.1
ALPHA INNOTECH REPORTS SECOND QUARTER PROFIT
ON 17% REVENUE GROWTH

August 12, 2008 – Alpha Innotech Corp., San Leandro, California

Alpha Innotech Corp. (OTCBB:APNO), a leading provider of bioanalytical systems for drug discovery and life science research, today reported financial results for the quarter ending June 30, 2008.

·  
Second quarter revenues were $4.2 million and increased 17% from the $3.6 million reported in the same period in 2007. 
 
·  
Alpha Innotech reported a gross profit of $2.4 million, or 56% of total revenue, compared with a gross profit of $2.0 million, or 55% of total revenue, for the 2007 second quarter.  The 20% improvement from the prior period was due primarily to increased sales volume and continued process efficiencies.
 
·  
Operating expenses for the quarter were $2.2 million, down 3% from $2.3 million for the second quarter of 2007. Interest expense increased to $175,000 from $67,000 due to interest paid and amortization of loan costs relating to the new debt facility with Agility Capital, LLC and Montage Capital, LLC.
 
·  
Net income for the second quarter of 2008 increased to $23,000, or less than $0.01 per share, from a net loss of $337,000, or $0.03 per share, for the second quarter of 2007.

Excluding interest, depreciation and stock-based compensation, on a non-GAAP basis, the Company had net income of $443,000 for the second quarter of 2008 compared to a net loss of $44,000 for the second quarter of 2007.  The non-GAAP net income (loss) is reconciled to comparable GAAP net income (loss) in the table entitled “Non-GAAP Calculation of Net Income (Loss)”.

“We are very pleased with our strong growth in both our Asia and North America markets,” said Ron Bissinger, Chief Executive Officer of Alpha Innotech.  “We’re also looking forward to sales of our new FluorChem® Q significantly contributing to our revenues for the remainder of 2008 and beyond.”

Year-to-Date Financial Results

For the six months ended June 30, 2008, total revenue was $7.9 million, an increase of 11% from $7.2 million for the comparable 2007 six month period.

Gross profit for the first half of 2008 was $4.5 million, a 13% increase from the gross profit of $4.0 million for the first half of 2007.  Operating expenses in the first half of 2008 were $4.3 million, a 4% increase from $4.2 million in the comparable 2007 period.
 
Net income for the first half of fiscal 2008 was $21,000 or less than $0.01 per share, an increase from a net loss of $338,000 or $.03 per share in the first half of 2007.

Interest expense for the first half of fiscal 2008 increased to $258,000 from $149,000 due to interest paid and amortization of loan costs relating to the new debt facility with Agility Capital, LLC and Montage Capital, LLC.


 
Additional Second Quarter 2008 Achievements

n  
Began shipping FluorChem® Q, a unique imager that rivals laser-based scanners for quantitative chemiluminescent and fluorescent Western blot imaging.

n  
Began shipping AlphaSpec™, a compact UV/Visible spectrophotometer that uses an in-tip detection design allowing users to measure and recover biological samples.

n  
Closed a new debt facility with Agility Capital, LLC and Montage Capital, LLC intended to provide working capital for growth, particularly for the Company's rapid expansion in Asia, while reducing the Company's overall cost of capital.

More information on Alpha Innotech can be found at the Company’s website www.alphainnotech.com.

About Alpha Innotech Corp.

Founded in 1992 and with over 10,000 systems sold worldwide, Alpha Innotech is a leading developer, manufacturer and marketer of digital imaging and analysis systems for the life science research and drug discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide.
 
Use of Non-GAAP Financial Measures

To supplement the Company’s financial statements presented in accordance with GAAP, the Company is also providing non-GAAP financial information.  The presentation of non-GAAP financial information should be considered in addition to the Company’s GAAP results and is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with GAAP.  The Company believes that both management and investors benefit from referring to non-GAAP financial information that excludes certain expenses in their assessment of the Company’s performance.  The Company also believes that investors benefit from increased transparency into supplemental information used by management in its financial and operational decision making.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. These forward-looking statements involve a number of risks and uncertainties that include, but are not limited to, the Company’s ability to obtain additional financing if needed, the timing of the introduction and success of new products, and the Company's growth prospects, that could cause actual results to differ materially from those anticipated or planned by these forward-looking statements. Please also refer to the risk factors described in our filings with the Securities and Exchange Commission, including our recent Form 10-KSB and Forms 10-Q filed with the Securities and Exchange Commission. We do not intend to update the forward-looking information contained in this news release except as required by law.

Contact:

Alpha Innotech Corp.
Ron Bissinger, CEO
Tel: 510-483-9620


 
 

 


 
 
Alpha Innotech Corp.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share amounts)
 
   
Three Months Ended
June 30,
   
Six Months Ended
June 30,
 
 
   
2008
   
2007
   
2008
   
2007
 
Revenue
  $ 4,243     $ 3,612     $ 7,912     $ 7,159  
Cost of Goods Sold
    1,857       1,620       3,414       3,195  
Gross profit
    2,386       1,992       4,498       3,964  
Operating expenses:
                               
Sales and Marketing
    1,313       1,163       2,498       2,217  
Research and Development
    273       344       648       648  
General and Administrative
    603       753       1,170       1,285  
Total operating expenses
    2,189       2,260       4,316       4,150  
Income (loss) from operations
    197       (268 )     182       (186 )
Interest expense
    (175 )     (66 )     (258 )     (149 )
Other income (expense), net
    1       (3 )     (3 )     (3 )
Sale of patents
                100        
Net income (loss) applicable to common stockholders
  $ 23     $ (337 )   $ 21     $ (338 )
Net income (loss) per share:
                               
Basic
  $ 0.00     $ (0.03 )   $ 0.00     $ (0.03 )
Diluted
  $ 0.00     $ (0.03 )   $ 0.00     $ (0.03 )
Weighted average shares outstanding:
                               
Basic
    10,874       10,421       10,694       10,290  
Diluted
    11,281       10,421       10,898       10,290  
                                 


 
 

 


 
 
Alpha Innotech Corp.
Condensed Consolidated Balance Sheet
(in thousands)
 
   
June 30,
2008
   
    December 31,
  2007
 
   
(Unaudited)
       
Assets
           
Current assets:
           
Cash and cash equivalents
  $ 749     $ 168  
Restricted cash
    50       50  
Accounts receivable, net
    2,331       2,230  
Inventory, net
    1,137       1,006  
Prepaid expenses and other current assets
    165       219  
Total current assets
    4,432       3,673  
Property and equipment, net
    884       914  
Loan fees, net     110        
Other assets
    90       90  
Total assets
  $ 5,516     $ 4,677  
Liabilities and stockholders’ deficit
               
Current liabilities:
               
Accounts payable
  $ 1,452     $ 1,786  
Accrued liabilities
    849       1,330  
Current portion of debt
    2,247       1,407  
Deferred revenue
    1,093       1,027  
Other liabilities
    247       265  
Total current liabilities
    5,888       5,815  
    Debt, net of current portion
    148       308  
Total stockholders’ deficit
    (520 )     (1,446 )
Total liabilities and stockholders’ deficit
  $ 5,516     $ 4,677  




 
 

 


 
 
Alpha Innotech Corp.
Non-GAAP Calculation of Net Income (Loss)
(Unaudited)
(in thousands)
 
   
Three Months Ended
June 30,
   
Six Months Ended
June 30,
 
 
   
2008
   
2007
   
2008
   
2007
 
GAAP net income (loss)
  $ 23     $ (337 )   $ 21     $ (338 )
Interest
    175       67       258       149  
Depreciation
    108       131       245       275  
Stock-based compensation
    137       95       257       150  
Non-GAAP basis income (loss)
  $ 443     $ (44 )   $ 781     $ 236  


 
 

 

-----END PRIVACY-ENHANCED MESSAGE-----